CN108367151A - 神经调节设备 - Google Patents
神经调节设备 Download PDFInfo
- Publication number
- CN108367151A CN108367151A CN201680061734.8A CN201680061734A CN108367151A CN 108367151 A CN108367151 A CN 108367151A CN 201680061734 A CN201680061734 A CN 201680061734A CN 108367151 A CN108367151 A CN 108367151A
- Authority
- CN
- China
- Prior art keywords
- signal
- optionally
- nerve
- patient
- vagus nerve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000005036 nerve Anatomy 0.000 title claims description 274
- 230000000694 effects Effects 0.000 claims abstract description 197
- 210000001186 vagus nerve Anatomy 0.000 claims abstract description 132
- 238000000034 method Methods 0.000 claims abstract description 105
- 206010006482 Bronchospasm Diseases 0.000 claims abstract description 100
- 230000007885 bronchoconstriction Effects 0.000 claims abstract description 90
- 230000001515 vagal effect Effects 0.000 claims abstract description 74
- 230000004936 stimulating effect Effects 0.000 claims abstract description 63
- 210000004072 lung Anatomy 0.000 claims abstract description 53
- 230000001537 neural effect Effects 0.000 claims abstract description 25
- 239000000835 fiber Substances 0.000 claims description 207
- 230000000638 stimulation Effects 0.000 claims description 87
- 230000036982 action potential Effects 0.000 claims description 83
- 238000011282 treatment Methods 0.000 claims description 54
- 229940124630 bronchodilator Drugs 0.000 claims description 48
- 208000006673 asthma Diseases 0.000 claims description 40
- 239000008280 blood Substances 0.000 claims description 34
- 210000004369 blood Anatomy 0.000 claims description 34
- 238000001514 detection method Methods 0.000 claims description 30
- 210000005091 airway smooth muscle Anatomy 0.000 claims description 29
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 28
- 230000009467 reduction Effects 0.000 claims description 27
- 230000019491 signal transduction Effects 0.000 claims description 22
- 230000001734 parasympathetic effect Effects 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 18
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 239000001301 oxygen Substances 0.000 claims description 18
- 230000036387 respiratory rate Effects 0.000 claims description 15
- 239000001569 carbon dioxide Substances 0.000 claims description 14
- 230000003287 optical effect Effects 0.000 claims description 14
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 14
- 210000000621 bronchi Anatomy 0.000 claims description 13
- 230000002889 sympathetic effect Effects 0.000 claims description 13
- 230000005611 electricity Effects 0.000 claims description 11
- 230000002045 lasting effect Effects 0.000 claims description 11
- 238000012937 correction Methods 0.000 claims description 10
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000002513 implantation Methods 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 8
- 206010057315 Daydreaming Diseases 0.000 claims description 7
- 230000005062 synaptic transmission Effects 0.000 claims description 7
- 229940125388 beta agonist Drugs 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 4
- 210000005037 parasympathetic nerve Anatomy 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000006651 lactation Effects 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 abstract description 12
- 238000005516 engineering process Methods 0.000 abstract description 4
- 230000002638 denervation Effects 0.000 abstract description 3
- 201000009267 bronchiectasis Diseases 0.000 description 29
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 28
- 238000002560 therapeutic procedure Methods 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 17
- 230000036541 health Effects 0.000 description 14
- 230000036259 sexual stimuli Effects 0.000 description 14
- 230000002146 bilateral effect Effects 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 238000005424 photoluminescence Methods 0.000 description 11
- 229930003347 Atropine Natural products 0.000 description 10
- 208000009079 Bronchial Spasm Diseases 0.000 description 10
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 10
- 229960000396 atropine Drugs 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- 239000004044 bronchoconstricting agent Substances 0.000 description 9
- 230000003435 bronchoconstrictive effect Effects 0.000 description 9
- 230000001066 destructive effect Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 8
- 238000004891 communication Methods 0.000 description 8
- 230000008602 contraction Effects 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 8
- 229960002052 salbutamol Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001994 activation Methods 0.000 description 7
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 7
- 229960001058 bupropion Drugs 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000007383 nerve stimulation Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 244000025254 Cannabis sativa Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000005279 Status Asthmaticus Diseases 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000004007 neuromodulation Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000002301 combined effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000013479 data entry Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000003270 subclavian artery Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010003598 Atelectasis Diseases 0.000 description 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
- 101710152983 Beta-2 adrenergic receptor Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000005139 Lycium andersonii Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 235000003283 Pachira macrocarpa Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000486406 Trachea Species 0.000 description 1
- 240000001085 Trapa natans Species 0.000 description 1
- 235000014364 Trapa natans Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003801 laryngeal nerve Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000003794 neural signal transduction Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000584 nodose ganglion Anatomy 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009165 saligot Nutrition 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36053—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/0816—Measuring devices for examining respiratory frequency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/087—Measuring breath flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/091—Measuring volume of inspired or expired gases, e.g. to determine lung capacity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/388—Nerve conduction study, e.g. detecting action potential of peripheral nerves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4029—Detecting, measuring or recording for evaluating the nervous system for evaluating the peripheral nervous systems
- A61B5/4035—Evaluating the autonomic nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36057—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for stimulating afferent nerves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/3611—Respiration control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36135—Control systems using physiological parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/36167—Timing, e.g. stimulation onset
- A61N1/36171—Frequency
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Optics & Photonics (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562208057P | 2015-08-21 | 2015-08-21 | |
| US62/208057 | 2015-08-21 | ||
| PCT/IB2016/054957 WO2017033101A1 (en) | 2015-08-21 | 2016-08-18 | Neuromodulation device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108367151A true CN108367151A (zh) | 2018-08-03 |
Family
ID=56853696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680061734.8A Pending CN108367151A (zh) | 2015-08-21 | 2016-08-18 | 神经调节设备 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11878160B2 (enExample) |
| EP (2) | EP4052756B1 (enExample) |
| JP (1) | JP2018523542A (enExample) |
| KR (1) | KR20180044941A (enExample) |
| CN (1) | CN108367151A (enExample) |
| AU (1) | AU2016310626A1 (enExample) |
| BR (1) | BR112018003107A2 (enExample) |
| CA (1) | CA2996252A1 (enExample) |
| ES (2) | ES2914685T3 (enExample) |
| RU (1) | RU2018105336A (enExample) |
| WO (1) | WO2017033101A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045468A (zh) * | 2018-08-09 | 2018-12-21 | 西安八水健康科技有限公司 | 一种耳部迷走神经刺激系统及其装置 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3538211A1 (en) * | 2016-11-11 | 2019-09-18 | Galvani Bioelectronics Limited | Treatment of diseases mediated by thyroid and parathyroid hormones |
| US20230139790A1 (en) * | 2020-01-23 | 2023-05-04 | Saluda Medical Pty Ltd | Neuromodulation of Primary and/or Postsynaptic Neurons |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070027496A1 (en) * | 2005-07-28 | 2007-02-01 | Cyberonics, Inc. | Stimulating cranial nerve to treat pulmonary disorder |
| CN101124012A (zh) * | 2004-12-27 | 2008-02-13 | 范因斯坦医学研究院 | 通过电刺激迷走神经治疗炎症性疾病 |
| CN101674862A (zh) * | 2005-11-10 | 2010-03-17 | 电子核心公司 | 支气管收缩的电刺激治疗 |
| US20100217347A1 (en) * | 2006-12-16 | 2010-08-26 | Greatbatch, Inc. | Neurostimulation for the treatment of pulmonary disorders |
| US8483831B1 (en) * | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
| US20130238050A1 (en) * | 2009-03-20 | 2013-09-12 | ElectroCore, LLC. | Non-invasive vagal nerve stimulation to treat disorders |
| CN103517732A (zh) * | 2011-03-10 | 2014-01-15 | 电核有限责任公司 | 用于无创电容式电刺激的设备和方法以及它们用于对患者颈部的迷走神经刺激的用途 |
| US20150202437A1 (en) * | 2014-01-17 | 2015-07-23 | Cardiac Pacemakers, Inc. | Systems and methods for delivering pulmonary therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993002744A1 (en) | 1991-08-09 | 1993-02-18 | Cyberonics, Inc. | Treatment of anxiety disorders by nerve stimulation |
| US8812112B2 (en) * | 2005-11-10 | 2014-08-19 | ElectroCore, LLC | Electrical treatment of bronchial constriction |
| WO2009137819A1 (en) * | 2008-05-09 | 2009-11-12 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
| US20120302909A1 (en) * | 2009-11-11 | 2012-11-29 | Mayse Martin L | Methods and systems for screening subjects |
| US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
| JP2015008746A (ja) * | 2013-06-26 | 2015-01-19 | オリンパス株式会社 | 神経刺激装置、副作用予測装置および神経刺激装置の作動方法 |
| US9737716B2 (en) * | 2014-08-12 | 2017-08-22 | Cyberonics, Inc. | Vagus nerve and carotid baroreceptor stimulation system |
-
2016
- 2016-08-18 KR KR1020187007903A patent/KR20180044941A/ko not_active Withdrawn
- 2016-08-18 US US15/752,502 patent/US11878160B2/en active Active
- 2016-08-18 AU AU2016310626A patent/AU2016310626A1/en not_active Abandoned
- 2016-08-18 EP EP22169569.5A patent/EP4052756B1/en active Active
- 2016-08-18 ES ES16760189T patent/ES2914685T3/es active Active
- 2016-08-18 WO PCT/IB2016/054957 patent/WO2017033101A1/en not_active Ceased
- 2016-08-18 CN CN201680061734.8A patent/CN108367151A/zh active Pending
- 2016-08-18 CA CA2996252A patent/CA2996252A1/en not_active Abandoned
- 2016-08-18 RU RU2018105336A patent/RU2018105336A/ru not_active Application Discontinuation
- 2016-08-18 JP JP2018509502A patent/JP2018523542A/ja active Pending
- 2016-08-18 BR BR112018003107A patent/BR112018003107A2/pt not_active Application Discontinuation
- 2016-08-18 EP EP16760189.7A patent/EP3337556B1/en active Active
- 2016-08-18 ES ES22169569T patent/ES2982192T3/es active Active
-
2023
- 2023-12-12 US US18/537,151 patent/US20240131327A1/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101124012A (zh) * | 2004-12-27 | 2008-02-13 | 范因斯坦医学研究院 | 通过电刺激迷走神经治疗炎症性疾病 |
| US20070027496A1 (en) * | 2005-07-28 | 2007-02-01 | Cyberonics, Inc. | Stimulating cranial nerve to treat pulmonary disorder |
| CN101674862A (zh) * | 2005-11-10 | 2010-03-17 | 电子核心公司 | 支气管收缩的电刺激治疗 |
| US20100217347A1 (en) * | 2006-12-16 | 2010-08-26 | Greatbatch, Inc. | Neurostimulation for the treatment of pulmonary disorders |
| US8483831B1 (en) * | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
| US20130238050A1 (en) * | 2009-03-20 | 2013-09-12 | ElectroCore, LLC. | Non-invasive vagal nerve stimulation to treat disorders |
| CN103517732A (zh) * | 2011-03-10 | 2014-01-15 | 电核有限责任公司 | 用于无创电容式电刺激的设备和方法以及它们用于对患者颈部的迷走神经刺激的用途 |
| US20150202437A1 (en) * | 2014-01-17 | 2015-07-23 | Cardiac Pacemakers, Inc. | Systems and methods for delivering pulmonary therapy |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045468A (zh) * | 2018-08-09 | 2018-12-21 | 西安八水健康科技有限公司 | 一种耳部迷走神经刺激系统及其装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2996252A1 (en) | 2017-03-02 |
| WO2017033101A1 (en) | 2017-03-02 |
| EP3337556B1 (en) | 2022-05-25 |
| EP4052756B1 (en) | 2024-05-15 |
| EP4052756A1 (en) | 2022-09-07 |
| EP3337556A1 (en) | 2018-06-27 |
| BR112018003107A2 (pt) | 2018-09-25 |
| KR20180044941A (ko) | 2018-05-03 |
| US11878160B2 (en) | 2024-01-23 |
| US20180236224A1 (en) | 2018-08-23 |
| ES2982192T3 (es) | 2024-10-15 |
| AU2016310626A1 (en) | 2018-03-08 |
| JP2018523542A (ja) | 2018-08-23 |
| RU2018105336A (ru) | 2019-09-23 |
| ES2914685T3 (es) | 2022-06-15 |
| US20240131327A1 (en) | 2024-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4299106B1 (en) | Accessing spinal network to enable respiratory function | |
| CN104508343B (zh) | 用于治疗咽部障碍的神经监测方法和系统 | |
| Pengo et al. | Randomised sham-controlled trial of transcutaneous electrical stimulation in obstructive sleep apnoea | |
| JP2018524113A (ja) | 呼吸機能を可能にするために脊髄ネットワークにアクセスすること | |
| JP2013525029A (ja) | 疼痛管理システム | |
| US20240131327A1 (en) | Neuromodulation Device | |
| CN109069821A (zh) | 神经调节设备 | |
| JP2018523542A5 (enExample) | ||
| Borel et al. | Influence of CO2 on upper airway muscles and chest wall/diaphragm corticomotor responses assessed by transcranial magnetic stimulation in awake healthy subjects | |
| Hudson et al. | Myths and methodologies: Invasive and non‐invasive assessment of respiratory muscle activity in humans | |
| Guntinas-Lichius et al. | Neurolaryngology | |
| Sittel | Orlando Guntinas-Lichius, Andreas H. Müller | |
| Sunshine | Electrical Activation and Analysis Paradigms for Restoration of Breathing | |
| Germann | Induction of plasticity in subcortical structures and its application in spinal cord injury | |
| Reier | Plasticity and Activation of Spared Intraspinal Respiratory Circuits Following Spinal Cord Injury | |
| BOOK | SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES &TECHNOLOGY (SCTIMST) | |
| Adury | Synergistic Activation of Inspiratory Muscles by an Adaptive Closed-loop Controller | |
| Mohammed Fuad | Logbook-NeuroTechnology | |
| Al-Anzari | Logbook-NeuroTechnology | |
| Shilpa | LOG BOOK | |
| Baekey | Brainstem control of cough and expiration reflex in the cat | |
| Kenaz Varghses | LOG BOOK | |
| Arya | LOG BOOK | |
| Vijila | LOG BOOK | |
| HK40018951B (en) | Accessing spinal network to enable respiratory function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180803 |